Ningxia Zhongke Biotechnology Balance Sheet Health
Financial Health criteria checks 1/6
Ningxia Zhongke Biotechnology has a total shareholder equity of CN¥167.3M and total debt of CN¥262.2M, which brings its debt-to-equity ratio to 156.7%. Its total assets and total liabilities are CN¥2.2B and CN¥2.0B respectively.
Key information
156.69%
Debt to equity ratio
CN¥262.21m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥14.12m |
| Equity | CN¥167.35m |
| Total liabilities | CN¥2.00b |
| Total assets | CN¥2.16b |
Recent financial health updates
No updates
Recent updates
Optimistic Investors Push Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Up 38% But Growth Is Lacking
Mar 02
Subdued Growth No Barrier To Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) With Shares Advancing 27%
Jan 16Revenues Not Telling The Story For Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) After Shares Rise 25%
Nov 13What Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 34% Share Price Gain Is Not Telling You
Aug 30Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Looks Just Right With A 50% Price Jump
Jul 12Calculating The Intrinsic Value Of Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165)
Jun 03Ningxia Zhongke Biotechnology Co., Ltd (SHSE:600165) Shares Slammed 30% But Getting In Cheap Might Be Difficult Regardless
Apr 21Ningxia Zhongke Biotechnology Co., Ltd's (SHSE:600165) 29% Cheaper Price Remains In Tune With Revenues
Feb 27Financial Position Analysis
Short Term Liabilities: 600165's short term assets (CN¥242.4M) do not cover its short term liabilities (CN¥2.0B).
Long Term Liabilities: 600165's short term assets (CN¥242.4M) exceed its long term liabilities (CN¥23.7M).
Debt to Equity History and Analysis
Debt Level: 600165's net debt to equity ratio (148.2%) is considered high.
Reducing Debt: 600165's debt to equity ratio has increased from 148.9% to 156.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 600165 has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: 600165 has less than a year of cash runway if free cash flow continues to grow at historical rates of 38.4% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/25 01:41 |
| End of Day Share Price | 2025/05/23 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ningxia Zhongke Biotechnology Co., Ltd is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Wei Liu | Haitong International Research Limited |